ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2466

Monoclonal Anti-MDA5 Autoantibodies Derived from a Patient with Dermatomyositis Target the Hel2i Domain of the MDA5 Protein
Abstract Number: 1588

Monocyte-derived Macrophages Accumulate in the Lungs in anti-MDA5+ Dermatomyositis with RP-ILD: Proinflammatory and Profibrotic Phenotype Revealed by Single-cell RNA Sequencing
Abstract Number: 2044

Monogenic Interferon Mediated Diseases: Novel Phenotype and Genotype Characteristics from Saudi Population
Abstract Number: 0551

Monogenic Lupus: Clinical Phenotypes and Genetic Mutations in a Cohort of Pediatric Patients
Abstract Number: 1106

Monosodium Urate and Calcium Pyrophosphate Crystal-induced Inflammation Relies on Cell Volume Regulation and LRRC8/VRAC Channel Activation
Abstract Number: 0048

Monosodium Urate Crystals Activate an Immune Tolerance Program That Restrains the Activation of Inflammatory Signaling in Macrophages During Gout Flares
Abstract Number: 1009

More Implementation Strategies Are Not Associated with Better Implementation Outcomes: Implementing the Lupus Patient Decision Aid
Abstract Number: 1857

More Than 50% of Rheumatoid Arthritis (RA) Patients with High or Moderate CDAI (clinical Disease Activity Index) Screen Positive on MDHAQ (multidimensional Health Assessment Questionnaire) Indices for FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen)
Abstract Number: 0609

Mortality After Autologous Hematopoietic Stem Cell Transplant for Autoimmune Disease: Do Scleroderma Patients Fare Worse?
Abstract Number: 1473

Mortality from Diseases of the Nervous System in Patients with Lupus in the past Two Decades
Abstract Number: 1953

Mortality Trends in Polymyositis and Dermatomyositis in Mexico: A General Population-based Study from 2000 to 2019
Abstract Number: 0119

Mortality-related Health Metrics in Systemic Autoimmune Diseases: An Epidemiological Analysis of a Nationwide Register-based Cohort
Abstract Number: 1980

Movement Evoked Pain as an Outcome Measure in Patients with Knee Osteoarthritis
Abstract Number: 1683

Moving the ACR’s Reproductive Health Guidelines into Practice: Assessment of a Novel Reproductive Rheumatology ECHO
Abstract Number: 1866

MRI Confirms MRE Evidence of Sacroiliitis in Many with Crohn’s Disease: A Prospective Study for the Screening of axSpA in High-risk Populations

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].